GET DAILY SIGNALSUnitedHealth Group (UNH) Q3 2026 Earnings: Key Metrics to Watch for Signs of Recovery
Key Takeaways
- UnitedHealth Group (NYSE: UNH) reports its third quarter 2026 results on Tuesday, October 13, before the market opens.
- Wall Street consensus points to earnings of roughly $4.12 per share on revenue near $111.5 billion.
- The prior quarter marked a sharp recovery, with adjusted earnings per share (EPS) of $6.38 and a much-improved medical care ratio of 86.7%.
- Investors will focus on the medical care ratio (MCR), Medicare Advantage enrollment, and momentum across the Optum businesses.
- Management raised its full-year 2026 adjusted EPS guidance to $19.50–$20.00 in July, setting a high bar for the second half of the year.
Earnings Context and Why It Matters
UnitedHealth Group stands as the largest U.S. health insurer and a diversified healthcare services company, with operations spanning its UnitedHealthcare insurance arm and the Optum care, pharmacy, and technology platforms. After facing elevated medical costs throughout 2025, the company posted a notable rebound in the second quarter of 2026, where adjusted EPS rose more than 50% year over year alongside an improved medical care ratio. That performance, paired with the raised full-year guidance, has turned investor focus toward whether cost discipline and Optum’s growth trajectory can hold steady. This upcoming report serves as an important checkpoint on the recovery story and the firm’s capacity to protect profitability in its Medicare, Medicaid, and commercial lines.
Earnings Expectations
Analysts anticipate UnitedHealth will report third quarter 2026 revenue of about $111.5 billion, reflecting a modest year-over-year decline of roughly 1.5% from the $113.2 billion posted in the same period last year. Consensus earnings estimates stand near $4.12 per share, a level that marks a meaningful step up from the depressed results of a year earlier when higher medical costs pressured margins.
Several metrics will draw close attention. The medical care ratio remains the key figure for insurers, representing the portion of premium revenue paid out for medical care. In the second quarter, UNH posted an MCR of 86.7%, down from 89.4% a year earlier, although that reading included roughly $860 million of favorable prior-period reserve development. Management’s full-year 2026 guidance assumes an MCR of 88.1%, plus or minus 25 basis points, which suggests costs in the second half could run higher than in the first. Medicare Advantage enrollment trends, pressure on Medicaid margins, and growth across Optum Health, Optum Rx, and Optum Insight will also be scrutinized, along with any comments on the full-year adjusted EPS range of $19.50 to $20.00. I also checked this using Tickeron’s AI Screener to see how UNH stacks up against peers in the sector.
Market Reaction and Investor Sentiment
Sentiment ahead of the release appears cautiously optimistic yet unsettled. UNH stock has seen its forward price-to-earnings multiple compress over the past year as investors weighed medical cost inflation and regulatory concerns. The solid second-quarter results were well received, but management continues to highlight ongoing headwinds such as elevated commercial medical cost trends, Medicaid margin pressure, and lower Medicare Advantage enrollment. Options activity and analyst notes reflect a broad range of expectations, with emphasis on whether the MCR remains contained and whether Optum can sustain operating leverage. A report that confirms cost control and reaffirms guidance could lend support to the shares, whereas any indication of renewed cost pressure might revive doubts about the durability of the rebound.
Forward Outlook and Key Factors to Monitor
Beyond the third-quarter numbers, attention will turn to whether UnitedHealth can keep the medical care ratio near the upper end of its targeted band through year-end. Management has already signaled a back-half-weighted cost trend, making the fourth quarter an important test of that outlook.
Medicare Advantage enrollment will remain a focal point. The company has guided for a decline of roughly 1.1 million members in 2026 as it shifts the business toward margin improvement, and progress toward a Medicare margin above 3% will indicate whether that approach is succeeding. Medicaid profitability also warrants watching, given that state rate actions have lagged behind cost trends.
On the services side, Optum’s expansion—especially in care delivery, pharmacy services, and technology offerings—could help offset insurance-side pressures. Management has highlighted efficiency efforts, including reduced prior-authorization volume, which may support operating margins over time. Any update to full-year guidance or remarks on 2027 pricing will help shape views on the longer-term earnings path. From what I see, monitoring these elements closely will clarify how sustainable the current recovery appears.
Using AI Tools in My Research
One tool I find particularly useful for this kind of analysis is Tickeron’s AI Screener. It helps me quickly filter stocks and ETFs by technical patterns, fundamentals, trends, and AI-driven signals, which adds efficiency when preparing for earnings releases like this one. I can scan for comparable names in the healthcare space and spot potential trade ideas without spending hours on manual work. The platform serves as a practical complement to traditional research and has become a regular part of how I evaluate opportunities around events like UNH’s quarterly update.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UNH in upward trend: price rose above 50-day moving average on October 14, 2026
UNH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UNH as a result. In 50 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for UNH just turned positive on October 05, 2026. Looking at past instances where UNH's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 182 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 116 of 245 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.
Bearish Trend Analysis
The 10-day RSI Indicator for UNH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 19 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 61 cases where UNH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
UNH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.711) is normal, around the industry mean (3.380). P/E Ratio (26.088) is within average values for comparable stocks, (124.266). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.023) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement